FDA Approved Products
1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
TIVORBEX
indomethacin
Peak
ORAL · CAPSULE
2014
NDA8/100
TOBI PODHALER
tobramycin
Peak
Viatris (2)
INHALATION · POWDER
2013
NDA8/100
TRAVATAN Z
travoprost
Peak
Novartis
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+1
2006
NDA8/100
TRELSTAR
triptorelin pamoate
Peak
Verity Pharmaceuticals
INTRAMUSCULAR · INJECTABLE
2010
NDA8/100
TRIESENCE
triamcinolone acetonide
Peak
INTRAVITREAL · INJECTABLE
2007
NDA8/100
TRIFERIC
ferric pyrophosphate citrate
Peak
Rockwell Medical
INTRAVENOUS · POWDER
2016
NDA8/100
TRIFERIC
ferric pyrophosphate citrate
Peak
Rockwell Medical
INTRAVENOUS · SOLUTION
2015
NDA8/100
TRIFERIC AVNU
ferric pyrophosphate citrate
Peak
Rockwell Medical
INTRAVENOUS · SOLUTION
2020
NDA8/100
TRIPTODUR KIT
triptorelin
Peak
R-Pharm US
INTRAMUSCULAR · FOR SUSPENSION, EXTENDED RELEASE
2017
NDA8/100
TRIUMEQ
abacavir sulfate, dolutegravir sodium, lamivudine
Peak
GSK
ORAL · TABLET
2014
NDA8/100
TRIUMEQ PD
abacavir sulfate, dolutegravir sodium, lamivudine
Peak
GSK
ORAL · TABLET, FOR SUSPENSION
2022
NDA8/100
TUDORZA PRESSAIR
aclidinium bromide
Peak
INHALATION · POWDER, METERED
2012
NDA8/100
TUZISTRA XR
chlorpheniramine polistirex; codeine polistirex
Peak
ORAL · SUSPENSION, EXTENDED RELEASE
2015
NDA8/100
TYGACIL
tigecycline
Peak
Pfizer
INTRAVENOUS · POWDER
2005
SMNDA8/100
TYKERB
lapatinib
Peak
Novartis
ORAL · TABLET
combination with: () capecitabine for the treatment of patients with advancedmetastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2)+4
2007
SMNDA8/100
UPTRAVI
selexipag
Peak
Johnson & Johnson
INTRAVENOUS · POWDER
2021
NDA8/100
VALCHLOR
mechlorethamine hydrochloride
Peak
Helsinn
TOPICAL · GEL
2013
NDA8/100
VANTRELA ER
hydrocodone bitartrate
Peak
Teva
ORAL · TABLET, EXTENDED RELEASE
2017
NDA8/100
VARUBI
rolapitant
Peak
TerSera Therapeutics
ORAL · TABLET
2015
NDA8/100
VERKAZIA
cyclosporine
Peak
OPHTHALMIC · EMULSION
2021
NDA8/100
VIRAMUNE XR
nevirapine
Peak
Boehringer Ingelheim
ORAL · TABLET, EXTENDED RELEASE
2011
NDA8/100
VIVITROL
naltrexone
Peak
Alkermes
INTRAMUSCULAR · FOR SUSPENSION, EXTENDED RELEASE
2006
NDA8/100
VOCABRIA
cabotegravir sodium
Peak
GSK
ORAL · TABLET
combination with EDURANT (rilpivirine) for short-term treatment of HIV-1 infection in adultsadolescents 12 years of age+9
2021
NDA8/100
VONJO
pacritinib
Peak
Akesobio
ORAL · CAPSULE
2022
SMNDA8/100